{"id":62746,"date":"2026-03-05T22:06:37","date_gmt":"2026-03-05T21:06:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/evommune-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-highlights\/"},"modified":"2026-03-05T22:06:37","modified_gmt":"2026-03-05T21:06:37","slug":"evommune-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-highlights","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/evommune-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-highlights\/","title":{"rendered":"Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights"},"content":{"rendered":"
\n

\n\u2013 Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD)<\/i><\/p>\n

\n\u2013 EVO756 on track to report Phase 2b top-line data in chronic spontaneous urticaria (CSU) and AD in 2Q26 and 2H26, respectively<\/i><\/p>\n

\n\u2013 Strengthened balance sheet with $125 million private placement to support additional clinical milestones and extend runway through 2028<\/i><\/p>\n

PALO ALTO, Calif. & NEW YORK–(BUSINESS WIRE)–Evommune, Inc. (NYSE: EVMN) (\u201cEvommune\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cThe positive top-line Phase 2a data for EVO301 marks an important milestone for Evommune and further validates IL-18 inhibition as a compelling approach for patients living with AD. We look forward to advancing the program forward and exploring an optimal dosing regimen for this potentially front-line biologic for AD,\u201d said Luis Pe\u00f1a, President and Chief Executive Officer at Evommune. \u201cWe\u2019ve nearly completed patient enrollment in the EVO756 Phase 2b trial in CSU, and plan to share top-line data in the second quarter. Additionally, the EVO756 Phase 2b trial in AD remains on track to report data in the second half of the year. MRGPRX2 antagonism is unique in its potential to modulate both mast cells and sensory neurons and we are eager to show the potential of MRGPRX2 inhibition in patients suffering from these debilitating diseases.”<\/p>\n

\nMr. Pe\u00f1a continued, \u201cWe recently strengthened our cash position with a $125 million private placement, which increases our ability to move EVO301 into deeper development and to expand our development programs as we look to make a major impact in the treatment of chronic inflammatory diseases. We continue to execute across our pipeline, underscoring our focus on delivering new medicines to patients, and I am very proud of the work being done by the entire Evommune team.\u201d<\/p>\n

\nBusiness Highlights, Recent Developments and Upcoming Milestones<\/span><\/b><\/p>\n

\nEVO756 \u2013 Oral MRGPRX2 Antagonist Program:<\/b><\/p>\n

\nFirst-in-class, potent and highly selective oral small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), a receptor predominantly found on mast cells and peripheral sensory neurons.<\/p>\n